Board of Directors
The Company’s Board of Directors is comprised of five members.

Dennis Langer, M.D., J.D.

Dennis H. Langer, M.D., J.D., has served as a member of our Board of Directors since February 2012. Dr. Langer brings over 25 years of experience in the pharmaceutical, biotechnology, and diagnostics industries in areas that include research & development, global and local marketing, and corporate development. Dr. Langer has served as a director of several public and private specialty pharmaceutical, biotechnology and diagnostic companies, and has been CEO and/or co-founder of several health care companies. From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Previously, he was President, North America, of Dr. Reddy’s Laboratories Limited. From September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline plc, and its predecessor, SmithKline Beecham including, most recently, as a Senior Vice President of Research & Development. Prior to SmithKline Beecham, Dr. Langer was President and CEO of Neose Technologies, Inc., and previously held research & development and marketing positions at Eli Lilly, Abbott Laboratories and GD Searle. At the beginning of his career, he was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health (NIH). Dr. Langer serves on the Board of Directors of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., and several private companies. Previously, Dr. Langer served as a Director of Myrexis, Inc., Auxilium Pharmaceutics, Inc., Sirna Therapeutics, Inc., Pharmacopeia, Inc., and Cytogen Corporation. Dr. Langer is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

James Gale

Mr. Gale is the founding Partner of Signet Healthcare Partners. Prior to founding Signet, Mr. Gale was head of principal investment activities and investment banking at Gruntal & Co., LLC. Prior to joining Gruntal, Mr. Gale originated and managed private equity investments for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior Investment Banker at E.F. Hutton & Co. Mr. Gale is currently the Chairman of the Board of Teligent, Inc. (NASDAQ:TLGT),  Alpex Pharma SA and Pfenex, Inc. and also serves on the board of directors of Arbor Pharmaceuticals, Spepharm AG and Knight Therapeutics. Mr. Gale holds a Masters of Business Administration from the University of Chicago.

John Celentano

Mr. Celentano currently works as an advisor to the pharmaceutical industry.  He has over 30 years of experience in the pharmaceutical industry, having held various senior leadership positions at Bristol-Myers Squibb including: President, Bristol-Myers Squibb Healthcare Group (Mead Johnson Nutrition, ConvaTec, and Medical Imaging) and Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada, and UK/Northern Europe.  He serves on the Boards of Teligent, Inc. (NASDAQ:TLGT) and privately held JJ White Inc. and YourEncore Inc.  He is Vice-Chairman of CMMB, an international nonprofit healthcare organization.  Mr. Celentano holds a B.A. from the University of Delaware and a MBA from Drexel University.

Frederick Sancilio, M.S., Ph.D.

Frederick D. Sancilio, M.S., Ph.D., is our founder and has served as our Chairman, President and Chief Executive Officer since November 2006. Dr. Sancilio has over 40 years of experience in the pharmaceutical research, development, manufacturing and distribution industries. Prior to founding the Company, Dr. Sancilio founded three successful pharmaceutical companies, one of which includes aaiPharma Inc., a contract research organization. Dr. Sancilio is an experienced pharmaceutical executive, development scientist and accomplished entrepreneur. He has published over 20 articles in peer reviewed scientific journals, holds 14 domestic and international patents and has presented to scientists in conferences around the world. Over the course of his career, he has contributed to the development of over 1,000 drugs marketed in the United States, Europe and Asia. Dr. Sancilio earned a Ph.D. in Physical and Analytical Chemistry and an M.S. from Rutgers University.

Patrick Gray

Patrick Gray has served as a member of our Board of Directors since 2012. Mr. Gray brings extensive experience in accounting and financial reporting to our Board, having spent over 37 years with PricewaterhouseCoopers LLP (PwC) until his retirement in 2009. He is a Certified Public Accountant who spent 25 years as an Audit Partner serving clients ranging from Fortune 500 companies and multi-national companies to rapid-growth companies pursuing an initial public offering (IPO). At the time of his retirement, he served as the lead partner for the PwC U.S. firm Corporate Governance Group. Prior to that time, he held various other leadership positions with the firm, including leadership of the PwC U.S. High Technology Group. Mr. Gray earned a B.S. from The Wharton School of Business at the University of Pennsylvania and is a Certified Public Accountant.

fpo
Sancilio & Company, Inc.
Google+   Likedin